These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27295402)

  • 61. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A comparison of methods for adaptive sample size adjustment.
    Friede T; Kieser M
    Stat Med; 2001 Dec; 20(24):3861-73. PubMed ID: 11782039
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determination of power and sample size in the design of clinical trials with failure-time endpoints and interim analyses.
    Gu M; Lai TL
    Control Clin Trials; 1999 Oct; 20(5):423-38. PubMed ID: 10503802
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome.
    Li Z; Quartagno M; Böhringer S; van Geloven N
    Clin Trials; 2022 Feb; 19(1):14-21. PubMed ID: 34693789
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
    Asakura K; Hamasaki T; Evans SR
    Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Group-sequential three-arm noninferiority clinical trial designs.
    Ochiai T; Hamasaki T; Evans SR; Asakura K; Ohno Y
    J Biopharm Stat; 2017; 27(1):1-24. PubMed ID: 26892481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
    Taylor DJ; Grobler A; Abdool Karim SS
    Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Methodological issues with adaptation of clinical trial design.
    Hung HM; Wang SJ; O'Neill RT
    Pharm Stat; 2006; 5(2):99-107. PubMed ID: 17080766
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Design and analysis of three-arm trials with negative binomially distributed endpoints.
    Mütze T; Munk A; Friede T
    Stat Med; 2016 Feb; 35(4):505-21. PubMed ID: 26388314
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Easily applicable multiple testing procedures to improve the interpretation of clinical trials with composite endpoints.
    Schüler S; Mucha A; Doherty P; Kieser M; Rauch G
    Int J Cardiol; 2014 Jul; 175(1):126-32. PubMed ID: 24861257
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improving the analysis of composite endpoints in rare disease trials.
    McMenamin M; Berglind A; Wason JMS
    Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
    Feißt M; Krisam J; Kieser M
    Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Modifying the design of ongoing trials without unblinding.
    Gould AL; Shih WJ
    Stat Med; 1998 Jan; 17(1):89-100. PubMed ID: 9463852
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.
    Zaslavsky BG
    Pharm Stat; 2013; 12(4):207-12. PubMed ID: 23625660
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Some aspects of the application of internal pilot studies.
    Lachenbruch PA; Wittes J
    Biom J; 2006 Aug; 48(4):556-7; discussion 558. PubMed ID: 16972705
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials.
    Kunzmann K; Grayling MJ; Lee KM; Robertson DS; Rufibach K; Wason JMS
    Stat Med; 2022 Feb; 41(5):877-890. PubMed ID: 35023184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.